Abstract
Introduction In 2022, the Government of Canada introduced the Interim Canada Dental Benefit (CDB) to support Canadian families with children < 12 years of age. This program operated from October 1, 2022, to June 30, 2024, with two application periods. The purpose of this study was to analyze data on applications accepted by the Canada Revenue Agency (CRA) during the first 18 months of the program.
Methods This study used available data sourced from the CRA for applicants as of March 29, 2024, and assessed as of April 5, 2024. Data covered the entirety of the first period (October 1, 2022–June 30, 2023) of the Interim CDB and the first nine months of the second period (July 1, 2023–March 29, 2024). The rate of child participation was calculated using population data from Statistics Canada (2021).
Results Over the first 18 months of the Interim CDB, a total of 410,920 applications were submitted and $403M distributed; $197M for 204,270 applications in period 1 and $175M for 173,160 applications in the first nine months of period 2. A total of 91.8% of applicants had a net family income < $70,000, receiving the maximum benefit amount. The provinces with the highest rate of child participation were Manitoba (77.1/1,000 period 1; 74.9/1,000 period 2), Ontario (82.5/1,000 period 1; 72.2/1,000 period 2), Nova Scotia (73.4/1,000 period 1; 71.1/1,000 period 2), and Saskatchewan (72.3/1,000 period 1; 68.2/1,000 period 2). Overall, there was an increase in the number of applications approved in period 2 compared to period 1.
Conclusions Uptake in the first three quarters of period 2 remained consistent and in many instances, revealed higher rates of applications by parents for the Interim CDB. Analyzing this data will aid in policy recommendation for enhancement of the Canadian Dental Care Program.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Saif Goubran holds B.Sc. Dent studentship from The Children’s Hospital Research Institute of Manitoba (CHRIM).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used only openly available data located at the Government of Canada Open Data Portal: https://open.canada.ca/data/en/dataset/69035265-2714-4ffa-af3f-fa850209b616, through Open Government Licence – Canada.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
